Xcout IntelAdial Pharmaceuticals, Inc
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Subscribe to see Adial Pharmaceuticals, Inc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Adial Pharmaceuticals, Inc at a glance
Adial Pharmaceuticals, Inc is a biotechnology company headquartered in Glen Allen, United States. It is publicly listed (ADIL) with a market capitalisation of $2.7M. Xcout tracks 26 named people at Adial Pharmaceuticals, Inc, including Cary John Claiborne (Chief Executive Officer, President & Director).
Adial Pharmaceuticals, Inc leadership
- Cary John ClaiborneChief Executive Officer, President & Director
- Cary J ClaiborneChief Executive Officer
- Vinay ShahChief Financial Officer & Treasurer
- John R. MartinChief Legal Officer
- Matthew DavidsonChief Development Officer & Director
- Jay KernFounder and General Partner of Kern Capital
20 more named people on record for Adial Pharmaceuticals, Inc, with roles, board committees and tenure — see the full roster →
Adial Pharmaceuticals, Inc competitors
A few of Adial Pharmaceuticals, Inc's closest competitors — see the full list of competitors and alternatives →
Navion Neurosciences, Inc. is a preclinical-stage biotechnology company located in Charlottesville, Virginia, that is developing next-generation, AI-enabled therapies.
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
NFL Biosciences develops botanical drug candidates derived from natural extracts to treat addictions, specifically targeting smoking cessation and the reduction of alcohol consumption. The company focuses on clinical-stage pharmaceutical research with the aim of licensing its innovative therapies to pharmaceutical partners.
Daya CNS, LLC is a preclinical biopharmaceutical company that develops a proprietary non-opioid pyridoindole platform for the treatment of chronic pain, substance abuse disorders, and neuropsychiatric conditions. Its product pipeline includes small molecule medications such as DDD-028 for neuropathic and inflammatory pain, DDD-024 for addiction, and DDD-016 for neuropsychiatric disorders, serving patients with unmet medical needs in neurology and addiction medicine.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Amalgent Therapeutics develops fixed-dose combination therapies that pair opioids with dopamine-modulating adjuvants to provide safe pain management. The company's lead program, AMGT-0220, is designed to reduce required opioid doses, mitigate tolerance development, and lower reward signaling to help patients recover without the risks of conventional opioid treatments.
Get Adial Pharmaceuticals, Inc's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Adial Pharmaceuticals, Inc in Xcout Intel
- 26 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access